| Literature DB >> 30579851 |
James Butler1, Bart Hens2, Maria Vertzoni3, Joachim Brouwers2, Philippe Berben2, Jennifer Dressman4, Cord J Andreas4, Kerstin Julia Schaefer5, James Mann6, Mark McAllister7, Masoud Jamei8, Edmund Kostewicz4, Filippos Kesisoglou9, Peter Langguth10, Mans Minekus11, Anette Müllertz12, Ronald Schilderink11, Mirko Koziolek13, Philipp Jedamzik13, Werner Weitschies13, Christos Reppas3, Patrick Augustijns14.
Abstract
The availability of in vitro tools that are constructed on the basis of a detailed knowledge of key aspects of gastrointestinal (GI) physiology and their impact on formulation performance and subsequent drug release behaviour is fundamental to the success and efficiency of oral drug product development. Over the last six years, the development and optimization of improved, biorelevant in vitro tools has been a cornerstone of the IMI OrBiTo (Oral Biopharmaceutics Tools) project. By bringing together key industry and academic partners, and by linking tool development and optimization to human studies to understand behaviour at the formulation/GI tract interface, the collaboration has enabled innovation, optimization and implementation of the requisite biorelevant in vitro tools. In this paper, we present an overview of the in vitro tools investigated during the collaboration and offer a perspective on their future use in enhancing the development of new oral drug products.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30579851 DOI: 10.1016/j.ejpb.2018.12.010
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571